Irinotecan

Generic Name
Irinotecan
Brand Names
Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
Drug Type
Small Molecule
Chemical Formula
C33H38N4O6
CAS Number
97682-44-5
Unique Ingredient Identifier
7673326042
Background

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...

Indication

For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
Associated Therapies
-
Clinical Trials
Related News

Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer

First Posted Date
2024-05-16
Last Posted Date
2024-05-16
Lead Sponsor
Pei-Rong Ding
Target Recruit Count
66
Registration Number
NCT06417476
Locations
🇨🇳

651 Dongfeng Road East, Guangzhou, Guangdong, China

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

First Posted Date
2024-05-06
Last Posted Date
2024-12-20
Lead Sponsor
Children's Oncology Group
Target Recruit Count
1656
Registration Number
NCT06401330

A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors

Phase 1
Not yet recruiting
Conditions
Advanced Malignant Neoplasm
Interventions
Drug: QLF31907
Drug: Irinotecan
Drug: Docetaxel
First Posted Date
2024-05-01
Last Posted Date
2024-05-01
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Target Recruit Count
60
Registration Number
NCT06394713

Photoradiation with Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

First Posted Date
2024-04-24
Last Posted Date
2024-12-11
Lead Sponsor
Mayo Clinic
Target Recruit Count
25
Registration Number
NCT06381154
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

First Posted Date
2024-04-17
Last Posted Date
2024-04-17
Lead Sponsor
Fudan University
Target Recruit Count
117
Registration Number
NCT06370754
Locations
🇨🇳

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China

Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer

Not Applicable
Recruiting
Conditions
Pancreatic Cancer
Adjuvant Therapy
Interventions
Drug: Irinotecan liposome injection
First Posted Date
2024-04-11
Last Posted Date
2024-04-11
Lead Sponsor
Kuirong Jiang
Target Recruit Count
53
Registration Number
NCT06361316
Locations
🇨🇳

FirstNanjingMU, Nanjing, Jiangsu, China

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

First Posted Date
2024-04-10
Last Posted Date
2024-12-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
450
Registration Number
NCT06356311
Locations
🇨🇳

Hunan Cancer Hospital ( Site 3014), Changsha, Hunan, China

🇨🇳

Xinjiang Medical University Cancer Hospital - Urumchi-The No.11 of Surgery building ( Site 3010), Urumchi, Xinjiang, China

🇩🇪

Städtisches Krankenhaus Kiel-2. Medizinische Klinik ( Site 1306), Kiel, Schleswig-Holstein, Germany

and more 111 locations

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

First Posted Date
2024-04-08
Last Posted Date
2024-07-01
Lead Sponsor
LaNova Medicines Zhejiang Co., Ltd.
Target Recruit Count
375
Registration Number
NCT06351020
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

🇨🇳

Shanghai East Hospital, Shanghai, Shanghai, China

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

First Posted Date
2024-04-04
Last Posted Date
2024-12-03
Lead Sponsor
AstraZeneca
Target Recruit Count
589
Registration Number
NCT06346392
Locations
🇻🇳

Research Site, Vinh, Vietnam

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

First Posted Date
2024-03-12
Last Posted Date
2024-07-18
Lead Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Target Recruit Count
488
Registration Number
NCT06304974
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy